Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
NCT ID: NCT01933672
Last Updated: 2016-09-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
33 participants
INTERVENTIONAL
2013-10-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
NCT01475461
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
NCT01338870
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
NCT01336738
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
NCT01076075
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
NCT00541450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-04937319 once-daily
PF-04937319 once-daily
Tablets, 300 mg once-daily with breakfast, 14-days
PF-04937319 split-dose
PF-04937319 split-dose
tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
Sitagliptin once-daily
Sitagliptin once-daily
tablets, 100 mg once-daily with breakfast, 14-days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-04937319 once-daily
Tablets, 300 mg once-daily with breakfast, 14-days
PF-04937319 split-dose
tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
Sitagliptin once-daily
tablets, 100 mg once-daily with breakfast, 14-days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with diabetic complications
* Female subjects who are pregnant or planning to become pregnant
* Subjects with unstable medical conditions (eg, hypertension)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Avail Clinical Research, LLC
DeLand, Florida, United States
Miami Research Associates, Inc.
South Miami, Florida, United States
MRA Clinical Research, LLC
South Miami, Florida, United States
High Point Clinical Trials Center, LLC
High Point, North Carolina, United States
Community Research
Cincinnati, Ohio, United States
Clinical Trials of Texas, Inc
San Antonio, Texas, United States
Diabetes and Glandular Disease Clinic
San Antonio, Texas, United States
Spaulding Clinical Research, LLC
West Bend, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1621019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.